Other Events ·
TransCode Therapeutics, Inc. adjourned its 2026 Annual Meeting of Stockholders to July 20, 2026, to allow Nasdaq to…
RNAZTranscode Therapeutics, Inc.
TransCode Therapeutics, Inc. adjourned its 2026 Annual Meeting of Stockholders to July 20, 2026, to allow Nasdaq to complete its review of the company's initial listing application. Preliminary voting reports indicate that all agenda proposals, including the conversion of Series A and Series B Non-Voting Convertible Preferred Stock into common stock, are receiving necessary support. TransCode Therapeutics, Inc. operates in the biotechnology industry and develops therapeutic solutions using advanced genetic technologies.